Ziel/Aim Restoration of iodine incorporation (redifferentiation) was achieved in previously radioiodine-refractory, unresectable thyroid carcinoma by mitogen-activated protein kinase (MAPK) inhibition. However, redifferentiation unsatisfactory BRAFV600E mutated (BRAF-MUT) thus far. Here we assess safety and efficacy therapy through genotype-guided MAPK-modulation patients with BRAF-MUT or wild ...